<DOC>
	<DOCNO>NCT00548899</DOCNO>
	<brief_summary>The purpose study determine efficacy safety sorafenib neoadjuvant setting patient primary breast cancer</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy Including Sorafenib Women With Previously Untreated Primary Breast Cancer</brief_title>
	<detailed_description>Epirubicin/Cyclophosphamide follow Paclitaxel ( EC/P ) well tolerate regimen high clinical activity . Histopathological complete remission preoperative chemotherapy direct correlation disease-free overall survival . The aim combine chemotherapy regime sorafenib neoadjuvant set increase locoregional systemic outcome patient</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Unilateral bilateral primary carcinoma breast , Tumor lesion breast palpable size &gt; = 2 cm . The lesion measurable twodimensions preferably sonography . In case inflammatory disease extent inflammation use measurable lesion ; Patients stag disease adjuvant chemotherapy would consider . Women childbearing potential must negative serum pregnancy test Negative HER2/neu status Karnofsky Performance status index &gt; = 80 % ; Normal cardiac function Laboratory requirement : Absolute neutrophile count ( ANC ) &gt; = 2,0 x 109/L Platelets &gt; = 100 x 109/L Hemoglobin &gt; = 10 g/dL ( &gt; = 6.2 mmol/L ) INR ≤ 1.5 ULN PTT ≤ 1.5 ULN within 14 day prior enrolment ASAT ALAT &lt; 2.5 x ULN Alkaline phosphatase ≤ 5 UNL . Patients ASAT and/or ALAT &gt; 1,5 x UNL associate alkaline phosphatase &gt; 2,5 x UNL eligible study Total bilirubin &lt; 1 X UNL Creatinine ≤ 175 µmol/L ( 2 mg/dl ) . The calculated creatinine clearance ≥ 60 mL/min . Paraffin tumor tissue block one serum one plasma sample centrally make available Complete stag workup within 3 month prior registration . Patients must available compliant treatment followup . Patients register trial must treat follow participate cooperate center . Patients low moderate risk , doubtful candidate adjuvant chemotherapy fulfil inclusion criteria No . 5 . Evidence distant metastasis ; Prior chemotherapy malignancy ; Prior radiation therapy breast cancer ; Preexisting rhagades hand foot skin problem ( e.g . psoriasis ) Pregnant lactate patient . Preexisting motor sensory neuropathy severity &gt; = grade 2 NCI criterion ; 7 . Concurrent treatment : Chronic corticosteroid unless initiate &gt; 6 month prior study entry low dose ( &lt; 20 mg methylprednisolone equivalent ) ; Sex hormone . Prior treatment must stop study entry ; Patients increase risk bleeding due concurrent therapeutic prophylactic anticoagulative treatment . Low dose coumarines permit . Other experimental drug anticancer therapy ; Drugs recognize strong inhibitor inducer isoenzyme CYP3A within last 5 day expect need 8 . Other serious illness medical condition : Previous malignant disease without diseasefree less 5 year ( except CIS Cervix nonmelanomatous skin cancer ) Known suspect congestive heart failure ( ≥NYHA II ) and/or coronary heart disease , angina pectoris require antianginal medication , previous history myocardial infarction , evidence transmural infarction ECG , un poorly control arterial hypertension , rhythm abnormality require permanent treatment , clinically significant valvular heart disease Thrombotic embolic event Hemorrhage/bleeding event ≥ Grade 3 within 4 week prior study entry Evidence history bleed diathesis coagulopathy History significant neurological psychiatric disorder Patients seizure disorder require medication steroid antiepileptic Currently active infection History HIV infection chronic hepatitis B C Serious non heal wound , ulcer bone fracture Patients prior immunosuppressive treatment Severe pulmonary condition/illness Disease significantly affect gastrointestinal function , Patients severe liver disease Major surgery , open biopsy significant traumatic injury within 4 week first dose study drug Definite contraindication use corticosteroid Inadequate general condition ( fit anthracycline/taxanecontaining chemotherapy )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Neoadjuvant chemotherapy</keyword>
	<keyword>Targeted therapy</keyword>
</DOC>